PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology
出版年份 2023 全文链接
标题
PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology
作者
关键词
-
出版物
Cancers
Volume 15, Issue 5, Pages 1397
出版商
MDPI AG
发表日期
2023-02-23
DOI
10.3390/cancers15051397
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials
- (2023) J.M. Versluis et al. ANNALS OF ONCOLOGY
- Comparative efficacy and safety of immune checkpoint inhibitors for unresectable advanced melanoma: A systematic review and network meta-analysis
- (2023) Yan Li et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- PCSK9 as an Atherothrombotic Risk Factor
- (2023) Tadeja Sotler et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- PCSK9: The Nexus of Lipoprotein Metabolism and Inflammation in COVID-19
- (2023) Sascha N. Goonewardena et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Immunomodulatory effect of locoregional therapy in the tumor microenvironment
- (2023) Lin Xie et al. MOLECULAR THERAPY
- Review to Understand the Crosstalk between Immunotherapy and Tumor Metabolism
- (2023) Pratibha Pandey et al. MOLECULES
- Effect of evolocumab on the progression of intraplaque neovascularization of the carotid based on contrast-enhanced ultrasonography (EPIC study): A prospective single-arm, open-label study
- (2023) Ju Chen et al. Frontiers in Pharmacology
- Biomaterial Strategies for Selective Immune Tolerance: Advances and Gaps
- (2023) Sean T. Carey et al. Advanced Science
- Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
- (2023) Meghan E Sise et al. Journal for ImmunoTherapy of Cancer
- Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment
- (2023) Almog Shalit et al. Cancers
- Assessing Potential Factors Influencing the Efficacy of Immune Checkpoint Inhibitors with Radiation in Advanced Non-Small-Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis
- (2023) Huilin Xu et al. Journal of Oncology
- Research progress of abnormal lactate metabolism and lactate modification in immunotherapy of hepatocellular carcinoma
- (2023) Yiwei Xu et al. Frontiers in Oncology
- Association of Lipoprotein(a) With Atherosclerotic Plaque Progression
- (2022) Yannick Kaiser et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PCSK9 as a Target for Development of a New Generation of Hypolipidemic Drugs
- (2022) Nikolay Kuzmich et al. MOLECULES
- The Potential Cardiotoxicity of Immune Checkpoint Inhibitors
- (2022) Inbar Nardi Agmon et al. Journal of Clinical Medicine
- PCSK9 participates in oxidized‐low density lipoprotein‐induced myocardial injury through mitochondrial oxidative stress and Drp1‐mediated mitochondrial fission
- (2022) Xuan Li et al. Clinical and Translational Medicine
- The Biological Relevance of PCSK9: When Less Is Better…
- (2022) Majambu MBIKAY et al. Biochemistry and Cell Biology
- Differential cholesterol uptake in liver cells: A role for PCSK9
- (2022) Aureli Luquero et al. FASEB JOURNAL
- Atherosclerotic Progression Is Related to Immune-Related Adverse Events
- (2022) Atsumasa Kurozumi et al. International Heart Journal
- Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction
- (2022) Lorenz Räber et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Lipoprotein(a) Cholesterol Masquerading as Low-Density Lipoprotein Cholesterol
- (2022) Guillaume Paré et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary
- (2022) Paul A. Heidenreich et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial
- (2022) Petr Ostadal et al. Lancet Diabetes & Endocrinology
- Targeting PCSK9 Ameliorates Graft Vascular Disease in Mice by Inhibiting NLRP3 Inflammasome Activation in Vascular Smooth Muscle Cells
- (2022) Yanqiang Zou et al. Frontiers in Immunology
- LDL-C Concentrations and the 12-SNP LDL-C Score for Polygenic Hypercholesterolaemia in Self-Reported South Asian, Black and Caribbean Participants of the UK Biobank
- (2022) Jasmine Gratton et al. Frontiers in Genetics
- Increased Circulating Levels of PCSK9 and Pro-Atherogenic Lipoprotein Profile in Pregnant Women with Maternal Supraphysiological Hypercholesterolemia
- (2022) Claudette Cantin et al. Antioxidants
- Self-Assembly of a Multifunction DNA Tetrahedron for Effective Delivery of Aptamer PL1 and Pcsk9 siRNA Potentiate Immune Checkpoint Therapy for Colorectal Cancer
- (2022) Wenjing Guo et al. ACS Applied Materials & Interfaces
- Tim-1 mucin domain-mutant mice display exacerbated atherosclerosis
- (2022) Hidde Douna et al. ATHEROSCLEROSIS
- Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond
- (2022) Nabil G. Seidah et al. Current Atherosclerosis Reports
- Combined Semi-mechanistic Target-Mediated Drug Disposition and Pharmacokinetic–Pharmacodynamic Models of Alirocumab, PCSK9, and Low-Density Lipoprotein Cholesterol in a Pooled Analysis of Randomized Phase I/II/III Studies
- (2022) Patrick Nolain et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Molecular and cellular biology of PCSK9: impact on glucose homeostasis
- (2022) Sègbédé E. R. Tchéoubi et al. JOURNAL OF DRUG TARGETING
- Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION phase III clinical trials
- (2022) F Raal et al. SAMJ SOUTH AFRICAN MEDICAL JOURNAL
- The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancer
- (2022) Chi Chun Wong et al. Nature Communications
- S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway
- (2022) Yan Sun et al. Cell Reports
- Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8+ T cells and the exclusion of Treg cells
- (2022) Rui Wang et al. Frontiers in Immunology
- Pembrolizumab versus cetuximab, concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase 2 trial
- (2022) Y. Tao et al. ANNALS OF ONCOLOGY
- PCSK9 conjugated liposomes for targeted delivery of paclitaxel to the cancer cell: A proof-of-concept study
- (2022) Nitin Bharat Charbe et al. BIOMEDICINE & PHARMACOTHERAPY
- Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease
- (2022) Michelle L. O’Donoghue et al. CIRCULATION
- Considerations for Use of Pharmacodynamic Biomarkers to Support Biosimilar Development— (I) A Randomized Trial with PCSK9 Inhibitors
- (2022) Morasa Sheikhy et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Cardiovascular complications of immune checkpoint inhibitors for cancer
- (2022) Franck Thuny et al. EUROPEAN HEART JOURNAL
- PCSK9 Affects Astrocyte Cholesterol Metabolism and Reduces Neuron Cholesterol Supplying In Vitro: Potential Implications in Alzheimer’s Disease
- (2022) Bianca Papotti et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K/AKT signaling in tumor cells and phenotypic polarization of macrophages
- (2022) Lu Wang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Clinical advances and ongoing trials of mRNA vaccines for cancer treatment
- (2022) Cathrine Lund Lorentzen et al. LANCET ONCOLOGY
- Global Circumferential and Radial Strain Among Patients With Immune Checkpoint Inhibitor Myocarditis
- (2022) Thiago Quinaglia et al. JACC-Cardiovascular Imaging
- Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study
- (2022) Ji Hyun Lee et al. Journal for ImmunoTherapy of Cancer
- PCSK9 Inhibition: From Current Advances to Evolving Future
- (2022) Chunping Liu et al. Cells
- Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents
- (2022) Shuai Wang et al. Frontiers in Cardiovascular Medicine
- Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways
- (2022) Vincenzo Quagliariello et al. Frontiers in Cardiovascular Medicine
- Immune myocarditis related to sintilimab treatment in a patient with advanced lung adenocarcinoma: A case report
- (2022) Yunling Lin et al. Frontiers in Cardiovascular Medicine
- PCSK9 inhibition might increase endothelial inflammation
- (2022) Johannes A. Schmid ATHEROSCLEROSIS
- Treatment of rheumatic adverse events of cancer immunotherapy
- (2022) Pankti Reid et al. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
- PCSK9: A emerging participant in heart failure
- (2022) Qian Xu et al. BIOMEDICINE & PHARMACOTHERAPY
- Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials
- (2022) Wolfgang Koenig et al. CARDIOVASCULAR DRUGS AND THERAPY
- PCSK9 Knockdown Can Improve Myocardial Ischemia/Reperfusion Injury by Inhibiting Autophagy
- (2022) Guangwei Huang et al. Cardiovascular Toxicology
- Association of Lipoprotein (a) With Coronary-Computed Tomography Angiography–Assessed High-Risk Coronary Disease Attributes and Cardiovascular Outcomes
- (2022) Neng Dai et al. Circulation-Cardiovascular Imaging
- Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
- (2022) Kausik K Ray et al. EUROPEAN HEART JOURNAL
- Effects of PCSK9 Inhibition on Coronary Atherosclerosis Regression of Nontarget Lesions after Primary Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients
- (2022) Yongjun Li et al. JOURNAL OF INTERVENTIONAL CARDIOLOGY
- Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment
- (2022) Shakir Ahamad et al. Journal of Medicinal Chemistry
- Lipid‐lowering treatment among older patients with atherosclerotic cardiovascular disease
- (2022) Michael G. Nanna et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Tumor-Suppressive and Immune-Stimulating Roles of Cholesterol 25-hydroxylase in Pancreatic Cancer Cells
- (2022) Noreen McBrearty et al. MOLECULAR CANCER RESEARCH
- Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial
- (2022) Andreas Hagen Røssevold et al. NATURE MEDICINE
- Review of recent clinical trials and their impact on the treatment of hypercholesterolemia
- (2022) Johnathon Seth Parham et al. PROGRESS IN CARDIOVASCULAR DISEASES
- Statin-Induced Geranylgeranyl Pyrophosphate Depletion Promotes PCSK9–Dependent Adipose Insulin Resistance
- (2022) Xin Shu et al. Nutrients
- Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data
- (2022) Juan Erviti et al. BMJ Open
- PCSK9 inhibitors for anti-inflammation in atherosclerosis: protocol for a systematic review and meta-analysis of randomised controlled trials
- (2022) Jichang Luo et al. BMJ Open
- TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
- (2022) Ming Yi et al. Frontiers in Immunology
- Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy
- (2022) Haohao Li et al. Frontiers in Immunology
- Targeting PCSK9 in Liver Cancer Cells Triggers Metabolic Exhaustion and Cell Death by Ferroptosis
- (2022) Malak Alannan et al. Cells
- Quantification of the growth suppression of HER2+ breast cancer colonies under the effect of trastuzumab and PD-1/PD-L1 inhibitor
- (2022) Regina Padmanabhan et al. Frontiers in Oncology
- A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines
- (2022) Louise Goksøyr et al. Vaccines
- What Are the Roles of Proprotein Convertases in the Immune Escape of Tumors?
- (2022) Elham Mehranzadeh et al. Biomedicines
- Molecular subtyping and IMScore based on immune-related pathways, oncogenic pathways, and DNA damage repair pathways for guiding immunotherapy in hepatocellular carcinoma patients
- (2022) Zeyan Yu et al. Journal of Gastrointestinal Oncology
- Immune Checkpoint Inhibitor Therapy in Oncology
- (2022) Sean Tan et al. JACC: CardioOncology
- Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor–Induced Myocarditis
- (2022) Alexi Vasbinder et al. JACC: CardioOncology
- A New Risk Factor for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy?
- (2022) Paaladinesh Thavendiranathan et al. JACC: CardioOncology
- Atherosclerosis With Immune Checkpoint Inhibitor Therapy
- (2022) Giselle Alexandra Suero-Abreu et al. JACC: CardioOncology
- Therapies for the Treatment of Cardiovascular Disease Associated with Type 2 Diabetes and Dyslipidemia
- (2021) María Aguilar-Ballester et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis
- (2021) R. Scott Wright et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Lipid signalling enforces functional specialization of Treg cells in tumours
- (2021) Seon Ah Lim et al. NATURE
- Impact of PCSK9 on CTRP9-Induced Metabolic Effects in Adult Rat Cardiomyocytes
- (2021) Susanne Rohrbach et al. Frontiers in Physiology
- Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study
- (2021) Stephen J. Nicholls et al. Cardiovascular Diagnosis and Therapy
- TAKOTSUBO CARDIOMYOPATHY AS EPIPHENOMENON OF CARDIOTOXICITY IN CANCER PATIENTS
- (2021) Andreina Carbone et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Inclisiran
- (2021) Bruce A. Warden et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- HMGB1/RAGE/TLR4 axis and glutamate as novel targets for PCSK9 inhibitor in high fat cholesterol diet induced cognitive impairment and amyloidosis
- (2021) Sally A. Abuelezz et al. LIFE SCIENCES
- Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study
- (2021) Paul J Cacciottolo et al. BMJ Open
- PCSK9 and cancer: Rethinking the link
- (2021) Khadijeh Mahboobnia et al. BIOMEDICINE & PHARMACOTHERAPY
- Serum levels of VCAM‐1 are associated with survival in patients treated with nivolumab for NSCLC
- (2021) Federico Carbone et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk
- (2021) John T. Wilkins et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Correction to: Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling
- (2021) Juanjuan Yuan et al. Protein & Cell
- Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors
- (2021) Dafne Jacome Sanz et al. Cancers
- Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients
- (2021) Alessandro Inno et al. Frontiers in Cardiovascular Medicine
- The Multifaceted Biology of PCSK9
- (2021) Nabil G Seidah et al. ENDOCRINE REVIEWS
- Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications
- (2021) Xiao-dan Xia et al. Frontiers in Cardiovascular Medicine
- A Resuscitated Case of Acute Myocardial Infarction with both Familial Hypercholesterolemia Phenotype Caused by Possibly Oligogenic Variants of the <i>PCSK9</i> and <i>ABCG5</i> Genes and Type I CD36 Deficiency
- (2021) Ryo Nishikawa et al. Journal of Atherosclerosis and Thrombosis
- Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies
- (2020) Tahir Mahmood et al. European Journal of Preventive Cardiology
- Nano-Encapsulation of Coenzyme Q10 in Secondary and Tertiary Nano-Emulsions for Enhanced Cardioprotection and Hepatoprotection in Human Cardiomyocytes and Hepatocytes During Exposure to Anthracyclines and Trastuzumab
- (2020) Vincenzo Quagliariello et al. International Journal of Nanomedicine
- Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models
- (2020) Vincenzo Quagliariello et al. Journal of Personalized Medicine
- PCSK9: Associated with cardiac diseases and their risk factors?
- (2020) Yanan Guo et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study
- (2019) Aldo Bonaventura et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Low doses of Bisphenol A have pro-inflammatory and pro-oxidant effects, stimulate lipid peroxidation and increase the cardiotoxicity of Doxorubicin in cardiomyoblasts
- (2019) V. Quagliariello et al. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY
- Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies
- (2019) Ellen Q. Wang et al. BIODRUGS
- PCSK9 inhibitor improves cardiac function and reduces infarct size in rats with ischaemia/reperfusion injury: Benefits beyond lipid‐lowering effects
- (2019) Siripong Palee et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels
- (2019) Kausik K. Ray et al. JAMA Cardiology
- Efficacy and Safety of Alirocumab in Patients With Autosomal Dominant Hypercholesterolemia Associated With Proprotein Convertase Subtilisin/Kexin Type 9 Gain-of-Function or Apolipoprotein B Loss-of-Function Mutations
- (2019) Michel Krempf et al. AMERICAN JOURNAL OF CARDIOLOGY
- PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy
- (2018) Zufeng Ding et al. CARDIOVASCULAR RESEARCH
- Relationship of PCSK9 levels with indices of vascular function and subclinical atherosclerosis in patients with familial dyslipidemias
- (2018) Charalambos Vlachopoulos et al. Hellenic Journal of Cardiology
- Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab
- (2018) Paul M Ridker et al. Journal of Clinical Lipidology
- Enhanced chemo-immunotherapy against melanoma by inhibition of cholesterol esterification in CD8+ T cells
- (2018) Man Li et al. Nanomedicine-Nanotechnology Biology and Medicine
- Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
- (2017) Marc S Sabatine et al. Lancet Diabetes & Endocrinology
- Association between familial hypobetalipoproteinemia and the risk of diabetes. Is this the other side of the cholesterol–diabetes connection? A systematic review of literature
- (2016) Davide Noto et al. ACTA DIABETOLOGICA
- Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials
- (2016) Paul M. Ridker et al. AMERICAN HEART JOURNAL
- Cholesterol production, accumulation, reverse transport, and excretion: opportunities for statins, PPAR- agonists, and PCSK9 inhibitors
- (2015) T. F. Luscher EUROPEAN HEART JOURNAL
- Proprotein Convertase Subtilisin/Kexin Type 9 Deficiency Reduces Melanoma Metastasis in Liver
- (2015) Xiaowei Sun et al. NEOPLASIA
- Several genetic polymorphisms interact with overweight/obesity to influence serum lipid levels
- (2012) Rui-Xing Yin et al. Cardiovascular Diabetology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started